ClinicalTrials.gg
RecruitingNCT07674264Updated Aug 21, 2026

Cross-System Effects of Acute Intermittent Hypercapnia-Based Interventions in PD

An interventional study of Acute intermittent hypercapnic hypoxia (AIHH) and Acute intermittent hypercapnic normoxia (AIHN) in Parkinson Disease and Parkinsonism, sponsored by University of Florida. Recruiting at 2 sites in United States. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by University of Florida · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Parkinson Disease by University of Florida — 5 open to participants now, 6 under way, none of them phase 3. Parkinson Disease · University of Florida.

Planned enrollment
18th of 33
32 · median 35
Started
2026
with 2 others
No phase
25 of 41
5 open now
Registered
41st of 41
by date

Among the 41 studies in Parkinson Disease by University of Florida, this one is the 18th largest by planned enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2026, is one of 25 with no phase, and was the 41st registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

5 of the 41 studies in Parkinson Disease by University of Florida are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Parkinson Disease by University of Florida, or all of them as a file.
02

Study summary

Parkinsonism impairs upper airway and axial motor control, leading to disordered breathing, reduced speech volume, and ineffective cough. Symptoms are poorly addressed by current therapies. This randomized pilot trial tests whether a single session of acute intermittent hypercapnic hypoxia (AIHH) or hypercapnic normoxia (AIHN) improves upper airway and axial motor function in Parkinsonism, and explores biomarker correlates of intervention responsiveness.

03

Conditions studied

  • Parkinson Disease
  • Parkinsonism

Keywords

  • Axial function
  • Upper airway
  • Breathing
  • Acute Intermittent Hypercapnic Hypoxia
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. adults 40 to 75 years of age (the latter to reduce the likelihood of cardiovascular disease)
  2. diagnosis of idiopathic Parkinsonism with Hoehn and Yahr stages 2-4
  3. medically stable with physician clearance
  4. ability to ambulate at least 10 feet with/without assistance
  5. ability to follow directions
  6. willing to abstain from blood donation for the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. additional neurologic conditions
  2. severe illness or infection, including respiratory/cardiovascular/lung disease, or uncontrolled hypertension
  3. inspiratory stridor
  4. pregnancy due to unknown tAIH effects on a fetus, although females of childbearing age will not be excluded*
  5. cigarette smoking or vaping within 5 years
  6. history of head/neck/lung cancer with the exception of basal cell carcinoma
  7. is currently participating in another research study that could influence the results from this study
  8. has deep brain stimulation electrodes implanted or has a history of deep brain stimulation
  9. faints or becomes lightheaded at the sight of blood

    • If a female of indicates there is a chance she could be pregnant, she will be provided a pregnancy test and allowed to continue in the study if negative. This is because the fetal risks associated with intermittent hypoxia are unknown.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Group 1: Acute Intermittent Hypercapnic Hypoxia

    Each participant randomly allocated to this arm will breathe brief bouts of mild acute intermittent hypercapnic hypoxia as the intervention, with PRE and POST testing of upper airway, axial function, and blood-based biomarkers.

    Other: Acute intermittent hypercapnic hypoxia (AIHH)

  • Active comparator
    Group 2: Acute Intermittent Hypercapnic Normoxia

    Each participant randomly allocated to this arm will breathe brief bouts of mild acute intermittent hypercapnic normoxia as the intervention, with PRE and POST testing of upper airway, axial function, and blood-based biomarkers.

    Other: Acute intermittent hypercapnic normoxia (AIHN)

Interventions

  • OtherAcute intermittent hypercapnic hypoxia (AIHH)

    Participants randomized to Group 1 will breathe brief bouts of AIHH, involving 15, 1.5-min exposures to 9-10% O2 and 4-5% CO2, alternated with 1 minute of 21% O2 (room air).

  • OtherAcute intermittent hypercapnic normoxia (AIHN)

    Participants randomized to Group 2 will breathe brief bouts of AIHN, involving 15, 1.5-min exposures to 21% O2 and 4-5% CO2, alternated with 1 minute of 21% O2 (room air).

06

What researchers measure

Primary outcomes

  1. Change in speech loudness

    Within-subject differences in sound pressure level (decibels) pre/post intervention and differences between intervention groups (AIHH vs. AIHN) during sustained phonation and connected speech.

    Time frame: baseline and 60 minutes post-intervention

  2. Change in maximum phonation duration

    Within-subject differences in duration (s) of sustained "ah" pre/post intervention and differences in duration between intervention groups (AIHH vs. AIHN).

    Time frame: baseline and 60-minutes post-intervention

  3. Change in peak expiratory flow rate during voluntary cough

    Within-subject differences in peak expiratory flow rate (L/s) produced during maximal volitional cough production, pre/post intervention, and between group (AIHH vs. AIHN) differences in peak expiratory flow rate.

    Time frame: baseline and 60 minutes post-intervention

  4. Change in Five-Times Sit-to-Stand performance

    Within-subject differences in average time (s) to complete 5 times sit-to-stand task, pre/post intervention, and differences between intervention groups (AIHH vs. AIHN).

    Time frame: baseline and 60 minutes post-intervention

  5. Change in Timed Up and Go performance

    Within-subject differences in duration (s) of Timed Up and Go performance, pre/post intervention. This includes duration of time participants take to stand, walk 3m, turn, walk back 3m, and sit. Differences in duration will also be compared between intervention groups (AIHH vs. AIHN).

    Time frame: baseline and 60 minutes post-intervention

  6. Change in fast walking speed

    Within-subject differences in duration (s) of 10M walk test, pre/post intervention. Differences in duration will also be compared between intervention groups (AIHH vs. AIHN)

    Time frame: baseline and 60 minutes post-intervention

  7. Correlation between blood-based biomarkers and functional outcomes

    Relationship between baseline biomarkers (APOE and BDNF genotype, inflammatory cytokines, serum urate, and circulating α-synuclein) and differences in speech loudness (dB), phonation duration (s), TUG (s), 5x sit-to-stand, and 10M walk test, pre/post intervention in both AIHH and AIHN intervention groups.

    Time frame: Baseline and 60 minutes post-intervention; genotype assessed at baseline only

Secondary outcomes

  1. Change in words per breath during connected speech

    Within-subject differences in the total number of words produced per breath while reading aloud Grandfather Passage, pre/post intervention. Words per breath will also be measured and compared between intervention groups (AIHH vs. AIHN).

    Time frame: baseline and 60 minutes post-intervention

  2. Change in cough volume acceleration during voluntary cough

    Within-subject differences in cough volume acceleration (L/s²) during maximal volitional cough production, pre/post intervention, and between groups (AIHH vs. AIHN). Cough volume acceleration is calculated as peak expiratory flow divided by peak expiratory flow rise time.

    Time frame: Baseline and 60 minutes post-intervention

  3. Change in airway occlusion pressure

    Within-subject differences in mouth occlusion pressure (P0.1) measured in cmH2O, pre/post intervention, and between group differences (AIHH vs. AIHN). P0.1 is the pressure generated at the mouth during the first 0.1 seconds of inspiration against an occluded airway.

    Time frame: Baseline and 60 minutes post-intervention

  4. Change in quiet breathing minute ventilation

    Within-subject differences in minute-ventilation (L/min ), pre/post intervention, and between group differences (AIHH vs. AIHN) measured during 20 minutes of quiet breathing. Minute ventilation is the calculated using breathing frequency (breaths per minute) x tidal volume (L).

    Time frame: Baseline and 60 minutes post-intervention

  5. Association between sleep characteristics and functional outcomes

    Relationship between sleep-related metrics (apnea-hypopnea index, oxygen saturation index, and sleep fragmentation) and differences in speech loudness (dB), phonation duration (s), TUG (s), 5x sit-to-stand, and 10M walk test, pre/post intervention in both AIHH and AIHN intervention groups. AHI is calculated by dividing total number of apneas/hypopneas by total hours of sleep. ODI is calculated by dividing the number of times %oxygen drops below baseline by total hours of sleep.

    Time frame: Overnight sleep assessment between acclimation and testing visit; functional outcomes measured at baseline and 60 minutes post-intervention

07

Study locations

2 of 2 sites recruiting
  • University of Florida
    Gainesville, Florida 32610, United States
    Recruiting
    • Michela Mir, CCC-SLP, PhD · Contactmichela.mir@ufl.edu · 352-273-6095
    • Alysha Bogard, PhD · Contactabogard@ufl.edu · 3038279875
    • Michela Mir, CCC-SLP · Principal investigator
    • Alysha Bogard, PhD · Principal investigator
  • Norman Fixel Institute for Neurological Diseases
    Gainesville, Florida 80303-2181, United States
    Recruiting
    • Michela Mir, CCC-SLP, PhD · Contactmichela.mir@ufl.edu · 303-827-9875
    • Alysha Bogard, PhD · Contactabogard@ufl.edu · 3038279875
    • Michela Mir, CCC-SLP · Principal investigator
    • Alysha Bogard, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data may be made available upon reasonable request following publication of the primary study results and with approval of the study investigators and University of Florida.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Available Starting: 12 months after publication of the primary study results. Available Ending: 5 years after publication of the primary study results.

Access criteria: De-identified individual participant data (IPD) that underlie the results reported in published manuscripts will be available beginning 12 months following publication of the primary study results and ending 5 years thereafter. Shared data may include demographic characteristics, intervention assignment, speech outcomes, cough outcomes, respiratory outcomes, mobility outcomes, sleep metrics, blood-based biomarker measures, and associated data dictionaries. Investigators who provide a methodologically sound proposal for secondary analyses may request access. Requests will be reviewed by the study investigators and the University of Florida as applicable. Approved investigators will receive access to de-identified datasets and supporting documentation through a secure data-sharing mechanism following execution of any required data use agreements and institutional approvals.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2028, 28 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 28 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 29, 2026
StartActual
Aug 12, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07674264
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Aug 12, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 21, 2026

Study contacts

Michlela Mir, CCC-SLP, PhD
Contact
michela.mir@ufl.edu
352-273-6095
Alysha Bogard, PhD
Contact
abogard@ufl.edu
3038279875
Michela Mir, CCC-SLP
principal investigator · University of Florida
Alysha Bogard, PhD
principal investigator · University of Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion